TheraGenetics Announces Agreement with King's College London to Participate in AddNeuroMed Consortium to Identify Biomarkers for Alzheimer’s Disease

Published: Sep 10, 2008

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today an agreement with King’s College London for its participation in the AddNeuroMed Consortium to identify biomarkers for Alzheimer’s disease that can be used to determine patient response to medications. TheraGenetics will undertake a pharmacogenetic study of Alzheimer’s patients treated with cholinesterase inhibitors in the study.

Back to news